

Annemarie Hanekamp
Chief Commercial Officer

| | |
|--|-------|
| Year of Birth | 1980 |
| Nationality | Dutch |
| Management Board Member of BioNTech SE since | 2024 |
| End of current appointment | 2028 |
| Memberships in statutory Supervisory Boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises | |
| n/a | n/a |

Annemarie Hanekamp is a seasoned pharmaceutical executive experienced in developing patient-focused commercial strategies for innovative oncology products encompassing sales, marketing and market access. As Chief Commercial Officer, she drives and executes the global commercialization strategy to leverage BioNTech’s full potential as a vertically integrated biopharmaceutical company.

Annemarie Hanekamp has more than 20 years of experience in the healthcare industry, including 15 years of commercial experience in companies ranging from early-stage biotechnology companies to full-scale pharmaceutical companies. She successfully delivered significant value in a broad range of roles: At Novartis, she led the U.S. and global teams through a time of strategic opportunities and operational headwinds following an unprecedented strong launch uptake of their novel treatment for prostate cancer. She was also responsible for building a new global oncology organization following a company-wide transformation. At Bristol-Myers Squibb Co., she held a pivotal role in evolving the company’s U.S. oncology strategy, resulting in significant and sustainable growth including an expanded market access as well as product launches.

Annemarie Hanekamp holds degrees in biomedical sciences as well as organizational leadership.